Kauliv (Teriparatide)

Teriparatide mimics the action of natural parathyroid hormone by binding to the PTH1 receptor on bone‑forming cells. This intermittent stimulation activates signaling pathways that increase osteoblast activity, promote new bone formation, and ultimately improve bone density and strength.

The specific dose and dosing schedule for Kauliv are determined by the prescribing healthcare professional based on the patient’s condition, weight, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for teriparatide in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Kauliv, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Kauliv (teriparatide) is an anabolic agent that builds new bone, whereas bisphosphonates and denosumab are anti‑resorptive drugs that slow bone breakdown. In patients with severe bone loss or fractures despite anti‑resorptive therapy, teriparatide can provide greater increases in bone density and fracture risk reduction.

Kauliv must be stored refrigerated between 2 °C and 8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to less than 24 hours.

Kauliv is given as a subcutaneous injection, typically into the thigh or abdomen. The injection is performed by a trained healthcare professional or the patient after proper instruction. The injection site should be rotated to minimize local reactions.

The most serious potential risks include hypercalcemia, severe allergic reactions, and the rare possibility of osteosarcoma observed in animal studies. Patients should be monitored for signs of high calcium levels, hypersensitivity, and any unexplained bone pain.

Kauliv is contraindicated in individuals with a history of skeletal malignancies, such as osteosarcoma, or those with unexplained high serum calcium. It should also be avoided in patients with severe renal impairment or active metabolic bone diseases other than osteoporosis.